We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

The major averages posted modest gains on Thursday, catching a tailwind from a cooler-than-anticipated inflation report.

A weight loss drug became the source of much contention in the proceedings of a Delhi High Court patent suit between a Danish pharmaceutical company, Novo Nordisk, and Indian companies, Reddy’s ...

“As generics enter the market post-2026, Novo Nordisk remains focused on delivering scientifically advanced high-quality therapies that go beyond weight loss to address broader metabolic and ...

Ozempic, Novo Nordisk's anti-diabetes drug, has been available in China since 2021. Ozempic sales in China reached 4.8 billion Danish kroner ($452 million) last year, twice as high as 2022.

Some Novo suits against compounders have fizzled Google keeps ex-Paul Weiss team Clear Channel wants fees in billboard battle May 29 (Reuters) - (Billable Hours is Reuters' weekly report on ...

Their study introduces a metalens-based microscope that achieves high-resolution imaging and a wide field of view within a compact design. The proposed metalens doublet configuration with annular ...

Herein, we designed and fabricated a top-filter-bottom (TFB) sandwich structure scintillator for high-resolution DEXI within a single exposure. More specifically, the low- and high-energy X-ray ...

More Bonds of Novo Nordisk Finance [Netherlands] B.V. About the Novo Nordisk Finance [Netherlands] B.V.-Bond (XS3002553538) The Novo Nordisk Finance [Netherlands] B.V.-Bond has a maturity date of ...